Vaxart Inc

Description

Aviragen Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of direct-acting antivirals to treat infections worldwide. Its product candidates include vapendavir, which is in Phase IIb SPIRITUS trial for an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA585, an oral fusion protein inhibitor, which is in Phase II development for the treatment and prevention of respiratory syncytial virus (RSV) infections; and BTA074, an antiviral treatment that is in Phase II development for condyloma caused by human papillomavirus types 6 and 11. Aviragen Therapeutics, Inc. has collaboration agreement with Daiichi-Sankyo for the development of Laninamivir octanoate, a neuraminidase inhibitor, which has completed Phase II clinical trial for the treatment of influenza. The company was formerly known as Biota Pharmaceuticals, Inc. and changed its name to Aviragen Therapeutics, Inc. in April 2016. Aviragen Therapeutics, Inc. is based in Alpharetta, Georgia.